证券代码：605016 证券简称：百龙创园 公告编号：2024-065 山东百龙创园生物科技股份有限公司 关于召开 2024 年三季度业绩说明会的公告 本次投资者说明会以网络互动形式召开，公司将针对 2024 年三季度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2024 年 11 月 11 日 上午 09:00-10:00 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开时间：2024 年 11 月 11 日(星期一) 上午 09:00-10:00 会 议 召 开 地 点 ： 上海证券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 04 日(星期一) 至 11 月 08 日(星期五)16:00 前 登录上证路演中心网站首页点击"提问预征集 ...

1、审议通过《关于 2024 年三季度报告的议案》 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事会会议召开情况 山东百龙创园生物科技股份有限公司（以下简称"公司"）第三届监事会第 十三次会议于 2024 年 10 月 30 日上午 10：00 在公司办公楼一楼第二会议室召 开，本次会议的会议通知和材料已于 2024 年 10 月 20 日通过邮件等方式发出。 监事会主席张德山先生担任本次会议召集人和主持人。本次会议应出席监事 5 人， 实际出席 5 人。 本次会议的召集、召开符合有关法律、行政法规、部门规章、规范性文件和 《公司章程》的规定，表决形成的决议合法、有效。 二、 监事会会议审议情况 证券代码：605016 证券简称：百龙创园 公告编号：2024-064 山东百龙创园生物科技股份有限公司 第三届监事会第十三次会议决议公告 经审议，监事会认为： 1）公司 2024 年三季度报告的编制和审议程序符合法律、法规、《公司章程》 和公司内部管理制度等各项规定； 2）公司 2024 年三季度报告的内容和格式符合 ...

Financial Performance - The company's operating revenue for Q3 2024 reached ¥289,039,012.89, representing a year-on-year increase of 19.92%[2] - The net profit attributable to shareholders for the same period was ¥63,029,321.01, reflecting a growth of 25.46% compared to the previous year[2] - The net profit after deducting non-recurring gains and losses was ¥61,597,465.11, which is an increase of 27.08% year-on-year[2] - Total operating revenue for the first three quarters of 2024 reached ¥820,387,384.32, a 25.5% increase from ¥653,792,099.94 in the same period of 2023[11] - Operating profit for the first three quarters of 2024 was ¥208,410,177.11, up 23.4% from ¥168,861,303.65 in the previous year[12] - Net profit attributable to shareholders for the first three quarters of 2024 was ¥182,591,645.07, representing a 29.2% increase compared to ¥141,339,479.77 in 2023[12] - The basic earnings per share for the first three quarters of 2024 was ¥0.57, compared to ¥0.45 in the same period of 2023[13] Cash Flow and Investments - The cash flow from operating activities for the year-to-date period was ¥166,644,630.68, showing a 15.80% increase[2] - Cash flow from operating activities totaled ¥847,472,782.81 in the first three quarters of 2024, compared to ¥658,899,880.93 in the same period of 2023, marking a 28.7% increase[14] - The net cash flow from operating activities was CNY 166,644,630.68, an increase from CNY 143,909,006.92 in the previous year, representing a growth of approximately 15.1%[15] - The total cash inflow from investment activities was CNY 685,771,844.49, compared to CNY 564,255,893.73 in the same period last year, indicating an increase of about 21.5%[15] - The cash outflow for investment activities totaled CNY 866,738,011.35, up from CNY 681,213,802.19, reflecting a rise of approximately 27.3%[15] - The net cash flow from investment activities was negative at CNY -180,966,166.86, worsening from CNY -116,957,908.46 year-over-year[15] - Cash and cash equivalents at the end of the period were CNY 105,078,895.40, down from CNY 225,148,141.47, a decrease of about 53.3%[16] - The company received CNY 90,000,000.00 in cash from borrowings, an increase from CNY 50,000,000.00 in the previous year, representing an 80% increase[15] - The cash outflow for financing activities was CNY 88,309,596.35, compared to CNY 32,714,725.56 last year, indicating a significant increase of approximately 169.5%[15] - The company paid CNY 67,750,025.75 in dividends and interest, up from CNY 31,792,526.09, which is an increase of about 112%[15] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥1,927,381,413.65, up 9.87% from the end of the previous year[3] - Current assets totaled CNY 856.61 million, up from CNY 773.74 million, indicating a growth of approximately 10.7%[8] - Accounts receivable increased significantly to CNY 257.29 million from CNY 167.20 million, representing a growth of about 54%[8] - Inventory rose to CNY 158.23 million, compared to CNY 152.05 million, marking an increase of approximately 4.2%[9] - Non-current assets totaled CNY 1.07 billion, up from CNY 980.44 million, showing an increase of about 9.2%[9] - Fixed assets surged to CNY 899.06 million from CNY 329.84 million, reflecting a substantial increase of approximately 172%[9] - Total liabilities increased to ¥306,301,533.46 in Q3 2024, compared to ¥246,352,113.80 in Q3 2023, reflecting a growth of 24.4%[10] - The company’s total liabilities increased, with accounts payable at CNY 122.56 million, down from CNY 186.95 million, indicating a decrease of approximately 34.4%[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,173[6] - The largest shareholder, Dou Baode, holds 47.34% of the shares, totaling 152,943,700 shares[6] - Total equity attributable to shareholders reached ¥1,621,079,880.19 in Q3 2024, up from ¥1,507,827,547.12 in Q3 2023, an increase of 7.5%[10] Government Support and R&D - The company received government subsidies amounting to ¥1,667,551.34 during the reporting period[4] - Research and development expenses for the first three quarters of 2024 were ¥25,439,807.94, slightly up from ¥24,621,458.89 in 2023[11] Other Financial Metrics - The weighted average return on equity for the reporting period was 4.09%, an increase of 0.54 percentage points[2] - The company reported a decrease in deferred income from ¥1,410,727.62 in Q3 2023 to ¥640,008.30 in Q3 2024, a reduction of 54.7%[10] - The impact of exchange rate changes on cash and cash equivalents was CNY 14,326.80, slightly up from CNY 13,345.30[16] - The net increase in cash and cash equivalents was CNY -12,616,805.73, a decline from CNY 44,249,718.20 in the previous year[16] - The company is focusing on expanding its market presence and developing new technologies, although specific figures were not disclosed in the report[8]

证券代码：605016 证券简称：百龙创园 公告编号：2024-062 山东百龙创园生物科技股份有限公司 关于 2024 年三季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上海证券交易所上市公司自律监管指引第 3 号——行业信息披露》之 《第十四号——食品制造》相关规定，现将山东百龙创园生物科技股份有限公司 （简称"公司"）2024 年三季度主要经营数据（未经审计）公告如下： 一、报告期主要经营数据 2024 年 1-9 月，实现营业收入 82,038.74 万元，同比增长 25.48%。实现主 营业务收入为 78,320.53 万元，同比增长 21.36%。实现归属于上市公司股东净 利润 18,259.16 万元，同比增长 29.19%。主营业务收入构成情况具体如下： 1、按产品分类情况 2、按地区分类情况 | | | 月 | | | | --- | --- | --- | --- | --- | | 2024 | 年 | 1-9 | 2023 年 1-9 | 月 | 1 单位：万元 项 ...

北京海润天睿律师事务所 关于山东百龙创园生物科技股份有限公司 2024 年第三次临时股东大会的法律意见书 中国·北京 北京市朝阳区建外大街甲 14 号广播大厦 5&9&10&13&17 层 邮编:100022 电话：(010)65219696 传真：（010）88381869 北京海润天睿律师事务所 关于山东百龙创园生物科技股份有限公司 2024 年第三次临时股东大会的法律意见书 致：山东百龙创园生物科技股份有限公司 本法律意见书仅用于为公司本次股东大会见证之目的，不得用于其他任何目 的或用途。本所同意，公司将本法律意见书作为公司本次股东大会的公告材料， 随其他需公告的信息一起向公众披露。 本所及经办律师依据《公司法》《中华人民共和国证券法》《律师事务所从 事证券法律业务管理办法》和《律师事务所证券法律业务执业规则》等规定及本 法律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了 勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见所认定的事 实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导 性陈述或者重大遗漏，并承担相应法律责任。现按照律师行业公认的业务标准、 ...

证券代码：605016 证券简称：百龙创园 公告编号：2024-060 山东百龙创园生物科技股份有限公司 2024 年第三次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 2、公司在任监事 5 人，出席 4 人，监事杜倩女士因工作原因本次会议请假； 3、董事会秘书谷俊超先生出席本次会议；其他高管列席本次会议。 二、 议案审议情况 审议结果：通过 | 1、出席会议的股东和代理人人数 | 94 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 203,625,946 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 63.0252 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长窦宝德先生主持，采取现场投票和 网络投票相结合的方式进行表决。本次股东大会的召集、召开以及表决方式符合 (一) 股 ...

证券代码：605016 证券简称：百龙创园 公告编号：2024-059 山东百龙创园生物科技股份有限公司 关于泰国子公司完成注册资本增资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 山东百龙创园生物科技股份有限公司（以下简称"公司"或"百龙创园"）于近 日收到子公司百龙创园（泰国）有限公司（以下简称"百龙泰国"）完成注册资本增 资的通知，具体情况如下： 1 | 序 | 股东名称 | 本次增资前出资额 | 本次增资后出资额 | | --- | --- | --- | --- | | 号 | | （万泰铢） | （万泰铢） | | 1 | 山东百龙创园生物科技股份有限公司 | 49,499.999 | 59,999.999 | | 2 | HARMONY ETERNAL INTERNATIONAL CO., | 0.001 | 0.001 | | | LIMITED | | | | | 合计 | 49,500.00 | 60,000.00 | 注册地址：888 Moo 8,Tambol Bo Thong,Amphu ...

北京海润天睿律师事务所 关于山东百龙创园生物科技股份有限公司 实际控制人及部分董事、高级管理人员 增持股份的法律意见书 中国·北京 北京市朝阳区建外大街甲 14 号广播大厦 5 层&9 层&10 层&13 层&17 层 电话：010-65219696；传真：010-88381869 实际控制人及部分董事、高级管理人员 增持股份的法律意见书 致：山东百龙创园生物科技股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受山东百龙创园生物科技 股份有限公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"证券法"）、 《上市公司收购管理办法》（以下简称"《管理办法》"）及《上海证券交易所 上市公司自律监管指引第 8 号——股份变动管理》（以下简称"《自律监管指引 第 8 号》"）等法律、法规和其他规范性文件规定，就公司实际控制人及部分董 事、高级管理人员（以下统称"增持人"）增持公司股份的行为（以下简称"本 次增持"）的相关事宜，出具本法律意见。 为出具本法律意见书，本所律师特作如下声明： 1.本所及本所律师对本法律意见书所涉及的有关事实 ...

证券代码：605016 证券简称：百龙创园 公告编号：2024-058 山东百龙创园生物科技股份有限公司 关于公司实际控制人及部分董事、高级管理人员增 持计划实施完毕暨增持结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●增持计划的基本情况：山东百龙创园生物科技股份有限公司（以下简称 "公司"）实际控制人及部分董事、高级管理人员计划自 2024 年 8 月 16 日起 6 个月内（法律法规及上海证券交易所业务规则等有关规定不允许增持的期间除 外），通过二级市场集中竞价交易方式增持公司股份，合计增持金额不低于人民 币 500.00 万元，不超过人民币 1,000.00 万元。具体内容详见公司于 2024 年 8 月 16 日在上海证券交易所网站（www.sse.com.cn）披露的《山东百龙创园生物 科技股份有限公司关于公司实际控制人及部分董事、高级管理人员计划增持公司 股份的公告》（公告编号：2024-039）。 ●增持计划实施结果情况：截至本公告披露日，自 2024 年 10 月 8 日至 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [1][6] Core Views - The company is a leading domestic producer of prebiotics, dietary fibers, and allulose, with a comprehensive product range. It has established strong partnerships with well-known domestic and international brands [5] - The company's revenue and net profit have shown consistent growth from 2020 to the first half of 2024, with revenue increasing from 500 million to 531 million yuan and net profit from 96 million to 120 million yuan during this period [5] - The company is expanding its production capacity to alleviate bottlenecks, with significant investments in new projects, including a subsidiary in Thailand and various production facilities in China [5][6] Financial Performance - Revenue for 2020-2024H1: 500 million, 653 million, 722 million, 868 million, and 531 million yuan, with year-on-year growth rates of 18.66%, 30.77%, 10.49%, 20.28%, and 28.73% respectively [5] - Net profit for the same period: 96 million, 104 million, 151 million, 193 million, and 120 million yuan, with year-on-year growth rates of 15.42%, 9.34%, 44.34%, 28.02%, and 31.24% respectively [5] - The company expects net profits of 277 million, 372 million, and 507 million yuan for 2024-2026, with corresponding EPS of 0.86, 1.15, and 1.57 yuan [6][11] Production Capacity and Expansion - The company has invested 495 million Thai Baht to establish a subsidiary in Thailand, focusing on producing allulose and other sugar products [5] - New projects include a 30,000-ton soluble dietary fiber project and a 15,000-ton crystalline sugar project, both of which have commenced production [5][8] - A planned investment of 212 million yuan for expanding production capacity of functional sugars is expected to enhance output significantly [5] Market Position and Competitive Landscape - The company has a diverse product line that meets various customer needs across multiple industries, including food, beverages, and pharmaceuticals [5] - It has established relationships with major brands such as Quest Nutrition, Halo Top, Wahaha, and Nongfu Spring, positioning itself as a key supplier in the industry [5] Valuation and Price Target - The company is valued at a reasonable range of 17.20 to 21.50 yuan based on a PE ratio of 20-25 times for 2024 [6][10]